Zymeworks’ ZW191 Gets FDA Fast Track for Cancer
VANCOUVER, British Columbia, March 30, 2026 Zymeworks Inc. announced that the U.S. FDA has granted Fast Track designation to...
FDA Fast Track
Advertisement
Rezpegaldesleukin Shows Strong Phase 2b Results in AD
San Francisco, USA | March 28, 2026 Phase 2b Data Demonstrates Strong Clinical Efficacy Nektar Therapeutics has announced compelling...
Nektar Therapeutics Reports Phase 2b Rezpegaldesleukin Data
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
FDA Fast Tracks ILD Imaging Radiotracer Innovation
LONDON, UK, Feb. 12, 2026 — Serac Healthcare announced that the U.S. Food and Drug Administration has granted Fast...
Ifetroban Gains FDA Fast Track for DMD Heart Disease
NASHVILLE, Tenn., Feb. 4, 2026 —Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has granted Fast...
Advertisements
Verismo Therapeutics Unveils Promising CAR T Advances for Solid Tumors at SITC 2025
Philadelphia, November 10, 2025 — Verismo Therapeutics, a clinical-stage biotechnology company pioneering KIR-CAR T cell therapies, presented compelling preclinical...
Gilead Showcases New Virology Data Spanning HIV, Hepatitis, and respiratory diseases
Foster City, California – October 20, 2025 — Gilead Sciences, Inc. (Nasdaq: GILD) announced that it will present new...
Star Therapeutics Raises $125M to Advance Bleeding Disorder Therapy
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2025 — Star Therapeutics announced it has closed an oversubscribed $125 million Series...
FDA Fast Track Granted to CS-1103 for Meth Intoxication
CAMBRIDGE, Mass., Sept. 30, 2025 — Clear Scientific, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Oncolytics Biotech Shows Favorable Safety for Pelareorep in GI Tumors
SAN DIEGO, Sept. 2, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced updated clinical safety...
Advertisement
